Differentiated thyroid cancer: disease status 1 year after primary treatment and prognostic tools. Longitudinal data of the Italian Thyroid Cancer Observatory.
Thyroid World Congress ePoster Library. Puxeddu E. 06/22/19; 272138; 197
Efisio Puxeddu
Efisio Puxeddu
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)

Background. Management of differentiated thyroid cancer (DTC) is driven by the likelihood of persistent/recurrent disease. Current practice guidelines are based on risk estimates obtained in studies of small cohorts or retrospective series. To assess their accuracy, we analyzed rates of structural disease 6-18 months after primary treatment in a large prospective cohort of DTC patients.

 

Methods. We analyzed data from the Italian Thyroid Cancer Observatory’s observational database, which prospectively enrolls newly diagnosed DTC in 45 Italian centers. Patients with 6-18 months of follow-up were included in the study.  Risk of persistent/recurrent disease and treatment responses were classified according to 2015 American Thyroid Association (ATA) guidelines. 

 

Results. 2730 patients (74% females, median age: 49 years) were enrolled. Primary surgery was total thyroidectomy in 2619 (95.9%) cases; neck dissection was performed in 1096 (40%). Most of the DTCs were papillary (2532, 92.7%). Radioiodine remnant ablation was perfomed in  1793 (65.7%) cases. Persistent/recurrent disease risk was low in 1386 (50.8%), intermediate in 1168 (42.8%), and high in 176 (6.4%). Responses to primary treatment recorded at 6-18 months were: excellent in 1675 (61.4%), biochemical incomplete in 63 (2.3%), indeterminate in 922 (33.8%), and structural incomplete in 70 (2.6%). High and intermediate risk statuses were associated with higher rates of structural disease at 6-18 months (17% and 2.7%, respectively, vs. 0.6% for low risk; odds ratios [95% confidence intervals]: 35.22 [15.41 - 90.66] and 4.85 [2.18 - 12.23], respectively; p <0.0001).

 

Conclusion. The 2015 ATA risk stratification system is an effective predictor of persistent/recurrent DTC. 

 


Background. Management of differentiated thyroid cancer (DTC) is driven by the likelihood of persistent/recurrent disease. Current practice guidelines are based on risk estimates obtained in studies of small cohorts or retrospective series. To assess their accuracy, we analyzed rates of structural disease 6-18 months after primary treatment in a large prospective cohort of DTC patients.

 

Methods. We analyzed data from the Italian Thyroid Cancer Observatory’s observational database, which prospectively enrolls newly diagnosed DTC in 45 Italian centers. Patients with 6-18 months of follow-up were included in the study.  Risk of persistent/recurrent disease and treatment responses were classified according to 2015 American Thyroid Association (ATA) guidelines. 

 

Results. 2730 patients (74% females, median age: 49 years) were enrolled. Primary surgery was total thyroidectomy in 2619 (95.9%) cases; neck dissection was performed in 1096 (40%). Most of the DTCs were papillary (2532, 92.7%). Radioiodine remnant ablation was perfomed in  1793 (65.7%) cases. Persistent/recurrent disease risk was low in 1386 (50.8%), intermediate in 1168 (42.8%), and high in 176 (6.4%). Responses to primary treatment recorded at 6-18 months were: excellent in 1675 (61.4%), biochemical incomplete in 63 (2.3%), indeterminate in 922 (33.8%), and structural incomplete in 70 (2.6%). High and intermediate risk statuses were associated with higher rates of structural disease at 6-18 months (17% and 2.7%, respectively, vs. 0.6% for low risk; odds ratios [95% confidence intervals]: 35.22 [15.41 - 90.66] and 4.85 [2.18 - 12.23], respectively; p <0.0001).

 

Conclusion. The 2015 ATA risk stratification system is an effective predictor of persistent/recurrent DTC. 

 


    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings